Grifols' CEO reassures no slowdown in China demand, focusing on growth in albumin and plasma products. CFO confirms debt target. CEO emphasizes optimizing cash flow through efficiency and cost control. Strong Q4 EBITDA expected with sales growth and margin improvement.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing